Therapy/Class: Immunomodulator / Immunostimulant
Mechanism of Action:
- Pidotimod is an immunomodulatory agent that enhances the body’s immune response.
- It stimulates the production of cytokines, such as interleukin-1 (IL-1) and interleukin-6 (IL-6), which activate immune cells, particularly T-lymphocytes and macrophages.
Indications:
- Chronic respiratory infections, such as recurrent upper respiratory infections
- Support for immune system function, particularly in immunocompromised individuals
- Adjunctive therapy in conditions with impaired immune response, such as asthma, chronic obstructive pulmonary disease (COPD), or other immunodeficiencies.
Dosage & Administration:
Recommended dosage
- In the treatment of acute respiratory infections, the recommended dosage is 400 mg (5 mL) twice daily for 15–20 days.
- For prophylaxis against relapse, the recommended dosage is 400 mg (5 mL) once daily (before breakfast) for 60 days.
How Supplied:
Pidolina is supplied in 200 mL bottles containing 400 mg of Pidotimod.
References:
- Lung India. 2019 Sep-Oct;36(5):422–433.
- Pak J Med Sci. 2019 Jul-Aug;35(4):981–986.